Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
US8940300B2 · kind B2 · utility
1Cited by
14References
9Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 15, 2011 |
| Grant date | Jan 27, 2015 |
| Priority date | — |
| Expiry date | Jul 15, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to humanized antibodies that specifically bind an EC1 domain of a mammalian Cadherin-11 protein and compositions (e.g., pharmaceutical compositions) comprising such antibodies. The invention also relates to methods for treating Cadherin-11-mediated disorders in a mammalian subject by administering a therapeutically effective amount of a humanized antibody of the invention. Cadherin-11-mediated disorders suitable for treatment by the methods of the invention include inflammatory disorders (e.g., inflammatory joint disorders, such as rheumatoid arthritis), fibrosis and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.